Literature DB >> 33804439

A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome.

Yun-Jung Yang1, Won-Young Lee2, Young-Jin Kim3, Yeon-Pyo Hong2.   

Abstract

Hyaluronic acid (HA) is commonly used for treating dry eye syndrome (DES). This meta-analysis was performed to compare the efficacies of HA- and non-HA-based eye drops, including saline and conventional artificial tears (ATs), for the treatment of dry eye disease. Eight databases (PubMed, EMBASE, Cochrane Central Register of Controlled Trials, DBpia, KoreaMed, KMBASE, RISS, KISS) were searched for studies comparing the efficacies of HA- and non-HA-based ATs in patients with DES published up to September 2020. Two independent reviewers assessed the quality and extracted the relevant data. The mean differences of Schirmer's (SH) test scores, tear breakup times (TBUT), corneal fluorescein staining scores (Oxford scale, 0-4), and ocular surface disease indexes were calculated. The standard mean difference and 95% confidence interval were calculated using a random effect model. Nineteen studies, including 2078 cases, were included. HA eye drops significantly improved tear production compared with non-HA-based eye drops (standard mean difference (SMD) 0.18; 95% confidence interval (CI) 0.03, 0.33). In a subgroup analysis, the SH test scores and TBUT values after using HA significantly increased compared to those measured after using saline (SMD 0.27; 95% CI 0.05, 0.49 and SMD 0.28; 95% CI 0.03, 0.52, respectively). Based on these results, HA eye drops may be superior to non-HA eye drops including normal saline and ATs. Further research is needed to assess the efficacies stratified by age, treatment duration, the severity of dry eye, and optimal dosages.

Entities:  

Keywords:  dry eye; hyaluronic acid; meta-analysis

Year:  2021        PMID: 33804439      PMCID: PMC7967738          DOI: 10.3390/ijerph18052383

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  40 in total

Review 1.  TFOS DEWS II Diagnostic Methodology report.

Authors:  James S Wolffsohn; Reiko Arita; Robin Chalmers; Ali Djalilian; Murat Dogru; Kathy Dumbleton; Preeya K Gupta; Paul Karpecki; Sihem Lazreg; Heiko Pult; Benjamin D Sullivan; Alan Tomlinson; Louis Tong; Edoardo Villani; Kyung Chul Yoon; Lyndon Jones; Jennifer P Craig
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 2.  The pathophysiology, diagnosis, and treatment of dry eye disease.

Authors:  Elisabeth M Messmer
Journal:  Dtsch Arztebl Int       Date:  2015-01-30       Impact factor: 5.594

Review 3.  Patient-reported symptoms in dry dye disease.

Authors:  Kelly K Nichols
Journal:  Ocul Surf       Date:  2006-07       Impact factor: 5.033

4.  Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness.

Authors:  Umberto Benelli; Marco Nardi; Chiara Posarelli; Timothy G Albert
Journal:  Cont Lens Anterior Eye       Date:  2010-02-12       Impact factor: 3.077

5.  An objective approach to dry eye disease severity.

Authors:  Benjamin D Sullivan; Diane Whitmer; Kelly K Nichols; Alan Tomlinson; Gary N Foulks; Gerd Geerling; Jay S Pepose; Valerie Kosheleff; Allison Porreco; Michael A Lemp
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-14       Impact factor: 4.799

6.  Sodium hyaluronate's effect on xerophthalmia: a meta-analysis of randomized controlled trials.

Authors:  Xiangyi Kong; Chengrui Yan; Wenbin Ma; Yongning Li; Bing Xing; Yi Yang; Renzhi Wang
Journal:  Curr Med Res Opin       Date:  2016-01-07       Impact factor: 2.580

7.  Effects of Lipid- Versus Sodium Hyaluronate-Containing Eye Drops on Optical Quality and Ocular Surface Parameters as a Function of the Meibomian Gland Dropout Rate.

Authors:  Kata Miháltz; Eva Maria Faschinger; Pia Veronika Vécsei-Marlovits
Journal:  Cornea       Date:  2018-07       Impact factor: 2.651

8.  A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease.

Authors:  Alessandro Lambiase; Benjamin D Sullivan; Tannin A Schmidt; David A Sullivan; Gregory D Jay; Edward R Truitt; Alice Bruscolini; Marta Sacchetti; Flavio Mantelli
Journal:  Ocul Surf       Date:  2016-09-08       Impact factor: 5.033

9.  Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca.

Authors:  J D Nelson; R L Farris
Journal:  Arch Ophthalmol       Date:  1988-04

10.  Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis.

Authors:  Dorothea Groß; Marc Childs; Jean-Marie Piaton
Journal:  Clin Ophthalmol       Date:  2018-06-11
View more
  9 in total

1.  Functionalized Hyaluronic Acid for "In Situ" Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome.

Authors:  Susi Burgalassi; Marco Fragai; Oscar Francesconi; Linda Cerofolini; Daniela Monti; Gemma Leone; Stefania Lamponi; Giuseppe Greco; Agnese Magnani; Cristina Nativi
Journal:  ACS Macro Lett       Date:  2022-09-14       Impact factor: 7.015

2.  Acupuncture for the management of dry eye disease.

Authors:  Julia Prinz; Nicola Maffulli; Matthias Fuest; Peter Walter; Frank Hildebrand; Filippo Migliorini
Journal:  Front Med       Date:  2022-09-24       Impact factor: 9.927

3.  Shear-Thinning and Temperature-Dependent Viscosity Relationships of Contemporary Ocular Lubricants.

Authors:  Wasim Kapadia; Ning Qin; Pei Zhao; Chau-Minh Phan; Lacey Haines; Lyndon Jones; Carolyn L Ren
Journal:  Transl Vis Sci Technol       Date:  2022-03-02       Impact factor: 3.283

4.  Corneal protective effects of novel tear substitutes containing sodium hyaluronate and dodecahydrosqualene, squalane, in a porcine dry eye model.

Authors:  Kiyomi Hagi; Takashi Hasegawa; Takeshi Yamamoto; Mizuki Tomihari; Yuka Fujimoto; Yuji Sakamoto; Shiro Sawa
Journal:  J Vet Med Sci       Date:  2021-11-18       Impact factor: 1.267

5.  Potential Ophthalmological Application of Extracts Obtained from Tuna Vitreous Humor Using Lactic Acid-Based Deep Eutectic Systems.

Authors:  Maha M Abdallah; Inês C Leonardo; Luna Krstić; Amalia Enríquez-de-Salamanca; Yolanda Diebold; María J González-García; Frédéric B Gaspar; Ana A Matias; Maria Rosário Bronze; Naiara Fernández
Journal:  Foods       Date:  2022-01-25

6.  Short-term Efficacy and Safety of Biological Tear Substitutes and Topical Secretagogues for Dry Eye Disease: A Systematic Review and Network Meta-analysis.

Authors:  Passara Jongkhajornpong; Thunyarat Anothaisintawee; Kaevalin Lekhanont; Pawin Numthavaj; Gareth McKay; John Attia; Ammarin Thakkinstian
Journal:  Cornea       Date:  2021-12-20       Impact factor: 3.152

7.  Therapeutic Hyper-CL soft contact lens in Sjögren's syndrome.

Authors:  Vito Romano; Davide Romano; Paolo Semeraro; Eliana Forbice; Antonio Iaria; Teodoro Pizzolante; Micol Frassi; Franco Franceschini; Francesco Semeraro
Journal:  Am J Ophthalmol Case Rep       Date:  2022-08-19

8.  Evaluation of the Lubricating Effect of Hyaluronic Acid on Contact Lenses Using a Pendulum-Type Friction Tester Under Mimicking Physiological Conditions.

Authors:  Hiroko Iwashita; Kiyoshi Mabuchi; Takashi Itokawa; Yukinobu Okajima; Takashi Suzuki; Yuichi Hori
Journal:  Eye Contact Lens       Date:  2022-02-01       Impact factor: 2.018

9.  Clinical efficacy of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: a protocol for a single-centre, randomised controlled trial.

Authors:  Maria Miura; Takenori Inomata; Shuko Nojiri; Jaemyoung Sung; Masashi Nagao; Jun Shimazaki; Akie Midorikawa-Inomata; Yuichi Okumura; Kenta Fujio; Yasutsugu Akasaki; Mizu Kuwahara; Tianxiang Huang; Masahiro Nakamura; Masao Iwagami; Kunihiko Hirosawa; Keiichi Fujimoto; Akira Murakami
Journal:  BMJ Open       Date:  2022-01-31       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.